GlassScriptPhysician profile
Maureen A Walker
NPI 1316472301
$844.35
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $111 · 2023: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $159.30 | 2021-2023 | Mounjaro |
| Novo Nordisk INC | $156.02 | 2021-2022 | |
| Abbvie INC. | $117.49 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.25 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $55.17 | 2021-2023 | Breztri |
| Pfizer INC. | $50.55 | 2021-2023 | |
| Amarin Pharma, INC. | $47.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.87 | 2021-2023 | Tradjenta, Jardiance |
| Otsuka America Pharmaceutical, INC. | $46.85 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.66 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.76 | 2022 | |
| Abbott Laboratories | $19.41 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.